Literature DB >> 21136664

Clinical proteomics: A need to define the field and to begin to set adequate standards.

Harald Mischak1, Rolf Apweiler, Rosamonde E Banks, Mark Conaway, Joshua Coon, Anna Dominiczak, Jochen H H Ehrich, Danilo Fliser, Mark Girolami, Henning Hermjakob, Denis Hochstrasser, Joachim Jankowski, Bruce A Julian, Walter Kolch, Ziad A Massy, Christian Neusuess, Jan Novak, Karlheinz Peter, Kasper Rossing, Joost Schanstra, O John Semmes, Dan Theodorescu, Visith Thongboonkerd, Eva M Weissinger, Jennifer E Van Eyk, Tadashi Yamamoto.   

Abstract

The aim of this manuscript is to initiate a constructive discussion about the definition of clinical proteomics, study requirements, pitfalls and (potential) use. Furthermore, we hope to stimulate proposals for the optimal use of future opportunities and seek unification of the approaches in clinical proteomic studies. We have outlined our collective views about the basic principles that should be considered in clinical proteomic studies, including sample selection, choice of technology and appropriate quality control, and the need for collaborative interdisciplinary efforts involving clinicians and scientists. Furthermore, we propose guidelines for the critical aspects that should be included in published reports. Our hope is that, as a result of stimulating discussion, a consensus will be reached amongst the scientific community leading to guidelines for the studies, similar to those already published for mass spectrometric sequencing data. We contend that clinical proteomics is not just a collection of studies dealing with analysis of clinical samples. Rather, the essence of clinical proteomics should be to address clinically relevant questions and to improve the state-of-the-art, both in diagnosis and in therapy of diseases.
Copyright © 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Year:  2007        PMID: 21136664     DOI: 10.1002/prca.200600771

Source DB:  PubMed          Journal:  Proteomics Clin Appl        ISSN: 1862-8346            Impact factor:   3.494


  76 in total

Review 1.  Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand?

Authors:  Nenad Vasic; Bernhard J Connemann; Robert C Wolf; Hayrettin Tumani; Johannes Brettschneider
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-12-16       Impact factor: 5.270

Review 2.  Rodent models and contemporary molecular techniques: notable feats yet incomplete explanations of Parkinson's disease pathogenesis.

Authors:  Sharawan Yadav; Anubhuti Dixit; Sonal Agrawal; Ashish Singh; Garima Srivastava; Anand Kumar Singh; Pramod Kumar Srivastava; Om Prakash; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2012-06-27       Impact factor: 5.590

Review 3.  The application of mass-spectrometry-based protein biomarker discovery to theragnostics.

Authors:  Jonathan M Street; James W Dear
Journal:  Br J Clin Pharmacol       Date:  2010-04       Impact factor: 4.335

4.  Proteome-wide identification of proteins and their modifications with decreased ambiguities and improved false discovery rates using unique sequence tags.

Authors:  Yufeng Shen; Nikola Tolić; Kim K Hixson; Samuel O Purvine; Ljiljana Pasa-Tolić; Wei-Jun Qian; Joshua N Adkins; Ronald J Moore; Richard D Smith
Journal:  Anal Chem       Date:  2008-02-14       Impact factor: 6.986

Review 5.  Mass spectrometry based proteomics in urine biomarker discovery.

Authors:  Dan Theodorescu; Harald Mischak
Journal:  World J Urol       Date:  2007-08-17       Impact factor: 4.226

6.  Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group.

Authors:  Melissa K Tuck; Daniel W Chan; David Chia; Andrew K Godwin; William E Grizzle; Karl E Krueger; William Rom; Martin Sanda; Lynn Sorbara; Sanford Stass; Wendy Wang; Dean E Brenner
Journal:  J Proteome Res       Date:  2009-01       Impact factor: 4.466

7.  Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias.

Authors:  Dale McLerran; William E Grizzle; Ziding Feng; William L Bigbee; Lionel L Banez; Lisa H Cazares; Daniel W Chan; Jose Diaz; Elzbieta Izbicka; Jacob Kagan; David E Malehorn; Gunjan Malik; Denise Oelschlager; Alan Partin; Timothy Randolph; Nicole Rosenzweig; Shiv Srivastava; Sudhir Srivastava; Ian M Thompson; Mark Thornquist; Dean Troyer; Yutaka Yasui; Zhen Zhang; Liu Zhu; O John Semmes
Journal:  Clin Chem       Date:  2007-11-02       Impact factor: 8.327

Review 8.  Advances in urinary proteome analysis and biomarker discovery in pediatric renal disease.

Authors:  Cécile Caubet; Chrystelle Lacroix; Stéphane Decramer; Jens Drube; Jochen H H Ehrich; Harald Mischak; Jean-Loup Bascands; Joost P Schanstra
Journal:  Pediatr Nephrol       Date:  2009-07-15       Impact factor: 3.714

Review 9.  Quality assessment for clinical proteomics.

Authors:  David L Tabb
Journal:  Clin Biochem       Date:  2012-12-12       Impact factor: 3.281

10.  Application of Proteomic Analysis to Renal Disease in the Clinic.

Authors:  Bruce A Julian; Hitoshi Suzuki; Goce Spasovski; Yusuke Suzuki; Yasuhiko Tomino; Jan Novak
Journal:  Proteomics Clin Appl       Date:  2009-01-01       Impact factor: 3.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.